EdisonTV

NeuroVive Pharmaceutical

EdisonTV | Pharmaceutical & healthcare | 29/11/2017

Executive Interview - NeuroVive Pharmaceutical

NeuroVive is a leader in mitochondrial medicine, with one project in clinical Phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT) and one project in clinical Phase I (KL1333) for genetic mitochondrial diseases. Here, CEO Erik Kinnman speaks about the company as it stands now and what the future holds for it.

» NeuroVive Pharmaceutical overview & latest research